Replies to post #99196 on Biotech Values

[iwfal]

Are GS9256 and GS9190 considered to be less potent when compared with other drugs in their class?

GS9190 is, I believe, a weaker drug than most DAAs in HCV (only 1.7 log at 8 days monotherapy in treatment naive).

OTOH these are the longest dual-DAA, wo SOC results released. The only previous results were 14 day results from Roche which showed striking results:


http://www.internationalbiotrust.com/press_releases/new/3_Nov_09.pdf

Note that the viral kinetic data from Roche showed no evidence of viral rebound during the 14 days - so either GILD's combo is just plain weaker or the rebound happened after 14 days and so wasn't seen in the Roche data (but this latter possibility seems unlikely because NONE of the patients in the strongest cohort of Roche data showed meaningful rebound in the 14 days).

All in all I'd expect GILDs drugs were just weaker. That said, it would be interesting to see the kinetic data from the GILD trial (which I believe that they have since they measured viral resistance over the trial).

[DewDiligence]

Are GS9256 and GS9190 considered to be less potent when compared with other drugs in their class?

The problem, as iwfal noted, is GS9190, the non-nuke. (GS9256, GILD’s PI, is OK, as far as I can tell.) Please see #msg-46036072 for background info.